AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17045905
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g olive oil
Trial: 12781165
Drug: Exposure group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure group (daily tasting of the target vegetable for 14 days)
Trial: 9863110
Drug: Xiaoliu Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoliu Tablet (XLT)
Trial: 8306925
Drug: haloperidol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (40 mg a day) + carbamazepine (400 mg a day)
Trial: 8306925
Drug: haloperidol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (40 mg a day) + bromocriptine (2.5 mg a day)
Trial: 8306925
Drug: haloperidol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (40 mg a day) + cyproheptadine (24 mg a day)
Trial: 8306925
Drug: haloperidol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (40 mg a day) + placebo
Trial: 30146495
Drug: Aripiprazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (5 mg uncoated tablets)
Trial: 30146495
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (300 mg uncoated tablets)
Trial: 25190346
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (48 IU)
Trial: 15941800
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (300 mg/d for 6 months)
Trial: 8983316
Drug: Diclofenac resinate
RxNorm normalized name: cholestyramine resin / diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac resinate 75mg taken once or twice daily
Trial: 8983316
Drug: Conventional enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional enteric‐coated diclofenac sodium 50mg tablets given two or three times daily
Trial: 1931143
Drug: Active aspirin
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active aspirin and active beta-carotene
Trial: 1931143
Drug: Active aspirin
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active aspirin and beta-carotene placebo
Trial: 1931143
Drug: Aspirin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin placebo and active beta-carotene
Trial: 25801942
Drug: Ethanol (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (doses: 6, 12, 18, 24, 30, and 42 g)
Trial: 21385352
Drug: Ward-based pharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ward-based pharmacy care from the clinical pharmacy team, including medication reconciliation at admission, daily medication review, and patient counselling at discharge.
Trial: 21385352
Drug: Standard pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmaceutical care (Control group).
Trial: 17405999
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg orally twice daily
Trial: 10888712
Drug: leflunomide (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leflunomide (loading dose 100 mg/day for 3 days, maintenance dose 20 mg/day)
Trial: 10888712
Drug: methotrexate (10-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate (10-15 mg/week)
Trial: 1526090
Drug: Ro 40‐5967
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40‐5967 (150 mg)
Trial: 1526090
Drug: Ro 40‐5967
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40‐5967 (200 mg)
Trial: 1526090
Drug: Ro 40‐5967
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40‐5967 (50, 100, 150, 200 mg)
Trial: 3549681
Drug: Imipramine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (3 mg/kg/day)
Trial: 26227577
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (no feedback scales)
Trial: 24030518
Drug: 10g gel-forming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g gel-forming pectin
Trial: 23160228
Drug: SYSADOA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYSADOA group chemicals administered orally for 13 weeks
Trial: 20560030
Drug: Intramyocardial BMMC
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial BMMC injection
Trial: 18630763
Drug: I.M ketoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M ketoprofen (100 mg) + interpleural bupivacaine (0.4 ml/kg)
Trial: 18630763
Drug: I.M pethidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M pethidine (1.5 mg/kg)
Trial: 18630763
Drug: I.M ketoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M ketoprofen (100 mg)
Trial: 18630763
Drug: interpleural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interpleural bupivacaine (0.4 ml/kg)
Trial: 11834852
Drug: Intralesional 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional 2.5 mg/ml verapamil hydrochloride injections administered at timed intervals
Trial: 11834852
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the same treatment except the verapamil hydrochloride
Trial: 11834852
Drug: Intralesional 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional 2.5 mg/ml verapamil hydrochloride injections
Trial: 2680158
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg once daily)
Trial: 2031046
Drug: Nebulized terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbutaline (5 mg inhaled 3 times daily) with PEP
Trial: 2031046
Drug: Nebulized terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbutaline (5 mg inhaled 3 times daily) without PEP
Trial: 30321947
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500mg twice a day
Trial: 30321947
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice a day
Trial: 28272250
Drug: Oxycodone IV-PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone IV-PCA (7.5 mg)
Trial: 28272250
Drug: Fentanyl IV-PCA
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl IV-PCA (100 μg)
Trial: 26433318
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control (review every 4 weeks, escalation of treatment if minimal disease activity criteria not met)
Trial: 26433318
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (standard therapy according to the treating clinician, review every 12 weeks)
Trial: 15084178
Drug: Daclizumab group
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab group (1 mg/kg daclizumab and 100 mg prednisolone for 3 days)
Trial: 15084178
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (steroids tapered to 0 mg at week 16)
Trial: 11165423
Drug: Low-Dose Oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Oral Alpha Interferon
Trial: 9884853
Drug: Tropisetron (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (2 mg)
Trial: 8004831
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil treatment for two years
Trial: 28351782
Drug: FP/FOR (1000/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/FOR (1000/40 μg)
Trial: 28351782
Drug: FP/FOR (500/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/FOR (500/20 μg)
Trial: 28351782
Drug: FP/SAL (1000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/SAL (1000/100 μg)
Trial: 24228894
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day of extended-release isosorbide mononitrate added to standard therapy, titrated to 60 mg/day at week 6 if blood pressure exceeded 140/90 mmHg
Trial: 24228894
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day of extended-release isosorbide mononitrate added to standard therapy
Trial: 21129756
Drug: IVIG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (2 g/kg)
Trial: 19726593
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (150 microg I daily for 28 weeks)
Trial: 17879366
Drug: Telaprevir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir (750 mg oral doses every 8 hours)
Trial: 17879366
Drug: Telaprevir and
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir and peginterferon alfa-2a (telaprevir 750 mg every 8 hours and peginterferon alfa-2a 180 mug weekly subcutaneous injections)
Trial: 16890357
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n=24) underwent conditioning with anaesthetic cream on one arm, followed by evaluation of pain intensity ratings.
Trial: 16890357
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=16) did not receive the conditioning treatment.
Trial: 10513866
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (MP) 125 mg intravenously
Trial: 7500368
Drug: Emotionally Focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotionally Focused Therapy for Couples (EFT)
Trial: 7179188
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative injection of BCG
Trial: 11818701
Drug: Lisinopril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (up to 20 mg/day)
Trial: 11818701
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (up to 90 mg/day)
Trial: 29126212
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day for 9 weeks
Trial: 26496098
Drug: 2-L Lactated
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L Lactated Ringer's (LR)
Trial: 26496098
Drug: 2-L Normal
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L Normal Saline (NS)
Trial: 26496098
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous fluid (noIVF)
Trial: 24045789
Drug: Late-evening snack
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Late-evening snack (LES) containing 200 kcal (50 g CHO)
Trial: 19050053
Drug: GIP +
RxNorm normalized name: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIP + 10 mg sulfonylurea (SU, glipizide)
Trial: 16702497
Drug: Adapalene gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene gel, 0.1%
Trial: 10776690
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) 3 mg/kg per day
Trial: 10776690
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 0.15 mg/kg per week
Trial: 1300623
Drug: Dietary and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary and/or drug intervention
Trial: 6542243
Drug: Cis-platinum at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis-platinum at 8 mg/m2 with 4 l of i.v. hydration
Trial: 6542243
Drug: Cis-platinum at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis-platinum at 6 mg/m2 without i.v. hydration
Trial: 23541975
Drug: Prolonged dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged dual antiplatelet therapy (DAPT)
Trial: 21832181
Drug: Control stimuli
RxNorm normalized name: STIMULEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control stimuli not showing biological motion
Trial: 19488984
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of levosulpiride tablet
Trial: 17096435
Drug: Sip volumes
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sip volumes <=2.0 mL
Trial: 15197790
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vascular-targeting agents with irradiation and other chemotherapeutic agents
Trial: 9462904
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) with adequate lung inflation
Trial: 8778745
Drug: Nifedipine treatment
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine treatment (10 mg t.i.d. for 5 days)
Trial: 2515939
Drug: Levonorgestrel 0.03
RxNorm normalized name: levonorgestrel 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 0.03 mg daily
Trial: 31509451
Drug: Delayed-treatment (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment (usual care)
Trial: 26265231
Drug: Platelet function
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet function monitoring with drug adjustment in patients with poor response to antiplatelet therapy
Trial: 26265231
Drug: Conventional strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional strategy without monitoring and drug adjustment
Trial: 26265231
Drug: Intensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of antiplatelet treatment based on platelet function
Trial: 10333376
Drug: CI‐988 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI‐988 (100 mg)
Trial: 10333376
Drug: CI‐988 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI‐988 (25 mg)
Trial: 1933997
Drug: Comparison drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison drug (Doxycycline or Amoxicillin-clavulanate)
Trial: 6214989
Drug: Moxalactam (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (1,000 mg intramuscular injection)
Trial: 6214989
Drug: Moxalactam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (1 g intravenous infusion)
Trial: 6214989
Drug: Cefazolin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (0.5 g intravenous infusion)
Trial: 10150324
Drug: Cefazolin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (0.5 g)
Trial: 6330478
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg q.i.d. as i.v. bolus followed by 150 mg orally twice daily
Trial: 6330478
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg q.i.d. intravenously and 1,000 mg daily orally in divided doses
Trial: 29625605
Drug: Otorhinolaryngologic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otorhinolaryngologic surgery without involvement of the oral cavity
Trial: 20431425
Drug: Fluarix (study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluarix (study vaccine)
Trial: 20431425
Drug: Fluzone (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzone (control vaccine)
Trial: 17507739
Drug: Carbohydrate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (1 g CHO/kg)
Trial: 10331734
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily oral rifapentine doses of 150, 300, or 600 mg given on day 1 and again on days 4-10
Trial: 10331734
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 600 mg dose given on days 1, 4, 7, and 10
Trial: 1683337
Drug: Zotepine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine (average daily dose of 168 +/- 15 mg)
Trial: 1683337
Drug: Zotepine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine (average daily dose of 241 +/- 70 mg)
Trial: 1683337
Drug: Perazine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perazine (average daily dose of 348 +/- 09 mg)
Trial: 7325348
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine during and after the operation
Trial: 7325348
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg of morphine
Trial: 12193097
Drug: Darusentan (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan (30, 100, 300 mg/day)
Trial: 8130044
Drug: Inhalation anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthesia with isoflurane and nitrous oxide (group 1)
Trial: 2782246
Drug: Sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isosorbide dinitrate (ISDN) in Group C (without sustained ISDN therapy)
Trial: 2782246
Drug: Sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isosorbide dinitrate (ISDN) in Group N (with sustained ISDN therapy)
Trial: 19884365
Drug: S/GSK1349572 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/GSK1349572 10 mg
Trial: 19884365
Drug: S/GSK1349572 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/GSK1349572 50 mg
Trial: 17077653
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (n = 27)
Trial: 12809357
Drug: ImmunoGuard (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ImmunoGuard (4 mg Andrographolide per tablet, 48 mg daily, taken 3 times of 4 tablets daily for 1 month)
Trial: 8637448
Drug: Voglibose (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.2 mg tablet before each test meal, 3 tablets per day)
Trial: 2452175
Drug: New biochemical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New biochemical method for assessing tissue damage via urinary excretion of hypoxanthine.
Trial: 28326950
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% lidocaine medicated plaster
Trial: 26265119
Drug: Transdermal granisetron
RxNorm normalized name: granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal granisetron (GTDS) - one GTDS patch for 7 days
Trial: 26265119
Drug: Palonosetron -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron - iv 0.25 mg/day for 1 day
Trial: 26265119
Drug: Transdermal granisetron
RxNorm normalized name: granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal granisetron (GTDS)
Trial: 16735938
Drug: Estradiol 0.05
RxNorm normalized name: estradiol 0.05 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 0.05 mg/day
Trial: 15592280
Drug: Raloxifene therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene therapy (60 mg/d every other day for 2 months followed by 60 mg/d)
Trial: 11808544
Drug: Raloxifene therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene therapy
Trial: 15592280
Drug: Slow-dose escalation
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-dose escalation of raloxifene therapy
Trial: 1648142
Drug: CAV (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV (cyclophosphamide 800 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 IV on day 1)
Trial: 1648142
Drug: PE (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE (cisplatin 80 mg/m2 IV on day 1, etoposide 100 mg/m2 IV on days 1, 3, and 5)
Trial: 6499602
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral prednisolone
Trial: 30119145
Drug: Epidural levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural levobupivacaine and morphine before incision (Group 1)
Trial: 30119145
Drug: Epidural levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural levobupivacaine and morphine after incision (Group 2)
Trial: 30119145
Drug: Epidural levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural levobupivacaine and morphine at the end of surgery (Group 3)